Parents Raise Money for Rare Disease Research through the Million Dollar Bike Ride at Penn Orphan Di


Parents of children with the rare disease Congenital Muscular Dystrophy are spending the next seven weeks preparing for the 5th Annual Million Dollar Bike Ride, to be held in Philadelphia on May 20th.

Parents of children with the rare disease Congenital Muscular Dystrophy (CMD), Susan Lee-Miller, Andy Parks, and Diane Smith-Hoban, are spending the next seven weeks preparing for the 5th Annual Million Dollar Bike Ride (MDBR), to be held in Philadelphia on May 20th.

The bike ride, hosted by the Penn Medicine Orphan Disease Center (ODC), is a 13-, 34-, or 72-mile route through the Greater Philadelphia region, and has raised more than $6.4 million for rare disease research since its inception in 2014. Lee-Miller, Parks, and Smith-Hoban each have a child affected by Collagen-VI Congenital Muscular Dystrophy (CMD), so they are riding with Team Cure CMD. Their goal is to raise $100,000 for COL6 CMD. To ride with Team Cure CMD and/or to donate, visit

Each rare disease team, including Team Cure CMD, must raise at least $20,000 to earn ODC matching dollars up to $50,000. The ODC ensures that all dollars raised go directly to the pilot grants, with no overhead costs. This unique opportunity to fundraise helps build awareness for causes that many people have never heard of. There is no limit to the size of a team, and Team Cure CMD members can be “virtual,” meaning they do not have to be present on ride day to join the fundraising effort.

On the day of the ride, Team Cure CMD cyclists, affected individuals, and their families and supporters will gather at 31st St. and Chestnut near the University of Pennsylvania campus. While cyclists complete their routes, non-riders can enjoy food and drinks donated by local vendors, indoor putt-putt and other games, video displays, and community-building. Rare disease team members connect, share information, and become friends. Parks’ wife, Jessie, says “The strength, inspiration, and hope that comes along with being around other people in the rare disease community is priceless.”

Smith-Hoban from Lafayette Hill, PA, rides with family and friends and says that the 13-mile ride is beautiful and relatively easy. “This route goes through Fairmount Park and shows off iconic Philadelphia scenes such as Boathouse Row and other well-known sites.”

Lee-Miller, hailing from Doylestown, PA, rides the tougher 34-mile while her husband, Scott completes the intense 72-mile trek. Their 20-year-old son Liam, who is in his second year at Temple University, hangs out with Smith-Hoban’s son, Luke, a 22-year-old recent Penn graduate. The two young men both live with CMD and have been good friends and wheelchair hockey teammates for more than 10 years.

Parks from Fairfax, VA, also rides the 72 miles through the greater Philadelphia area. His wife Jessie brings their young daughters Naya and Divia to provide moral support for the team. This will be their second year participating in the event, which they learned about when they saw a post in a CMD support group they had joined when Divia was first diagnosed. “We have been learning a lot. With each event we get ourselves involved in, the disease doesn’t feel as intimidating and we are not as helpless in our fight against it.”

For questions regarding participation in the MDBR as a cyclist, volunteer or sponsor, or regarding the pilot grant program, please contact Samantha Charleston at or (215) 573-6822.

Cure CMD
Related Videos
Signs and Symptoms of Connective Tissue Disease
How Gene and Cell Therapy Is Developing in Dermatology
Joyce Teng, MD, PhD, discusses how therapeutic advances in fields like epidermolysis bullosa should progress treatment discourse in other rare dermatoses.
The Prospect of Pz-cel in RDEB Treatment, with Peter Marinkovich, MD
Comparing New Therapies for Dystrophic Epidermolysis Bullosa
Reviewing 2023 with FDA Commissioner Robert M. Califf, MD
Dunia Hatabah, MD | Image Credit: HCPLive
Ricky Safer: What Clinicians Need to Know About PSC
Ryan T. Fischer, MD: Long-Term Odevixibat Benefit for Alagille Syndrome
Saeed Mohammad, MD: IBAT Inhibitors for Cholestatic Disease
© 2024 MJH Life Sciences

All rights reserved.